World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0000947958
Reproduction Date:

Title: Pramiracetam  
Author: World Heritage Encyclopedia
Language: English
Subject: Piracetam, Ampakine, Racetams, Racetam, PEPA (drug)
Collection: Acetamides, Amines, Ampa Receptor Agonists, Pyrrolidones, Racetams
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Pramistar
Legal status
  • US: Not FDA approved
Routes of
CAS Registry Number  N
ATC code N06
PubChem CID:
ChemSpider  Y
Chemical data
Formula C14H27N3O2
Molecular mass 269.383 g/mol

Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. It is marketed by Menarini under the brand name Pramistar as a treatment for memory and attention deficits in aging people with neurodegenerative and vascular dementias in Italy and some Eastern European countries.[1][2][3]

Pramiracetam was discovered by scientists at Parke-Davis, at that time a division of Warner-Lambert, in the late 1970s; patents expired in 1996. Warner-Lambert conducted clinical trials in Alzheimer's Disease and abandoned that indication after Phase II trials showed mixed results; it then began to develop it as an orphan drug as an adjunct to electroconvulsive therapy for major depressive disorder, in part to take advantage of the administrative exclusivity provided by the orphan status. It licensed European rights to Menarini which continued developing it for dementias, and in 1991 it licensed US and other non-European rights to Cambridge Neuroscience, Inc, (CNI) which pursued the ECT indication, as well as a use in restoring cognitive function after stroke or traumatic brain injury.[4] CNI obtained the orphan designation for the ECT use from the FDA in 1991, which was later withdrawn when CNI abandoned the drug.[5]

CNI conducted a clinical trial in 4 people who had cognitive problems following a head injury. Trials conducted by or on behalf of Menarini and Warner-Lambert included two small trials conducted in the Ukraine, one in people with cerebrovascular disease and another in people with concussion. Another small trial was performed on Italy, on healthy people in whom amnesia was induced with scopolamine.[6]


  1. ^ AIFA Pramistar authorizations in the Agenzia Italiana del Farmaco Database Page accessed August 2, 2015. Italian Label, linked from that site]
  2. ^ International listings for pramiracetam Page accessed August 2, 2015
  3. ^ Italian marketing authorization for the brand name Remen has been revoked per the AIFA database, as has the marketing authorization for the brand name Neupramir, per the AIFA database, each checked on August 2, 2015. Main page at AIFA for pramiracetam is here
  4. ^ Staff, The Pink Sheet. May 27, 1991 Cambridge Neuroscience Developing Warner-Lambert's Pramiracetam
  5. ^ FDA Orphan Drug Designations and Approvals Database Page accessed August 2, 2015
  6. ^ Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010 Feb 12;70(3):287-312. Review. PMID 20166767
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.